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Background: Oxidative stress and redox-regulating enzymes may potentially accelerate pancreatic carcinogenesis
and also affect chemoresistance. Recently major antioxidant response regulator NF-E2-related factor 2 (Nrf2) has
been linked to poor prognosis in pancreatic cancer. Nrf2 activity is strictly regulated by oxidative stress sensor
Kelch-like ECH-associated protein 1 (Keap1). Oxidative DNA damage can be estimated e.g. by 8-hydroxy-2′-
deoxyguanosine (8-OHdG) expression. The aim of this study was to evaluate the expression and possible prognostic
role of Keap1 and 8-OHdG in pancreatic cancer.
Methods: We assessed immunohistochemically the expression of 8-OHdG and Keap1 in precisely characterized
material of 69 pancreatic adenocarcinoma patients.
Results: Nuclear 8-OHdG associated with cytoplasmic Keap1 expression (p = 0.031) and was overexpressed in
patients with smaller tumors (p = 0.016) and in tumors without lymph node involvement (p = 0.051). Cytoplasmic
8-OHdG expression associated with higher differentiation (p = 0.023). Cytoplasmic Keap1 immunostaining associated
with N0-staging (p = 0.0009) and the absence of distant metastases (p = 0.018). Membranous Keap1 associated with
longer relapse-free survival (p = 0.041) and pancreatic cancer-specific survival (median survival 14 vs. 32 months;
p = 0.029) and was in multivariate analysis an independent prognostic factor of pancreatic cancer-related death
(HR 2.66, 95%CI 1.23-5.75).
Conclusions: Oxidative stress and main redox regulators may participate in pancreatic carcinogenesis and Keap1
appears as a promising prognostic factor in pancreatic cancer. Future studies should also concentrate on potential
link between redox regulation and chemoresistance in pancreatic cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/4220521801406476
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Although pancreatic adenocarcinoma is not the one of the
most common cancers, it has dismal prognosis, the five
year survival being about 5% [1]. At the moment of diag-
nosis, malignant tissue extends beyond the pancreas in
90% of the cases and metastasis can often be detected [2].
Because of local expansion and early appearance of metas-
tases, tumor is local enough for curative surgical resection
only in 10-20% of the cases. Adjuvant chemotherapy with* Correspondence: peeter.karihtala@oulu.fi
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provement in survival [3].
Reactive oxygen species (ROS) are produced mostly as
a consequence of aerobic metabolism in mitochondrial
respiratory chain. In addition to their crucial role in sig-
nal transduction, ROS production is a cornerstone of
radiotherapy and may also participate to gemcitabine
resistance via hypoxia-inducible factor 1α- and nuclear
factor κB- mediated CXCR4 up-regulation [4]. An expand-
ing amount of literature from in vitro experiments sug-
gests that ROS have a substantial effect on pancreatic
carcinogenesis [5-9]. However, compared to most other
solid tumors, these data from in vivo studies are rather
limited in pancreatic cancer.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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interaction with e.g. DNA can be reliably measured with
the use of antibodies against specific footprints of oxidative
damage. Hydroxyl radical (•OH) is the most reactive ROS
with a lifetime of less than 1 nanoseconds and it reacts
easily with pyrimidines, purines and chromatin protein
resulting in base modifications, genomic instability and
alterations in gene expression such as p53 tumor suppres-
sor gene [10,11]. Nucleoside 8-hydroxy-2′-deoxyguanosine
(8-OHdG) is a specific end-product of •OH -derived dam-
age in C8 carbonyl group of guanine and it is the most
studied marker against oxidative damage in DNA [12].
Keap1/Nrf2 pathway is the key sensor of intracellular
redox status. Under normal redox state, Keap1 (Kelch-like
ECH-associated protein 1) is bound to Nrf2 (nuclear fac-
tor erythoid-derived 2-like 2) and Nrf2 activity is re-
pressed by degradation in ubiquitin proteasome pathway
[13-16]. When exposed to oxidative stress, Keap1 is inacti-
vated and unable to bind Nrf2, which subsequently trans-
locates to nucleus and binds to antioxidant response
element (ARE) in DNA together with small Maf proteins
[13,15]. This results in induction of several cytoprotective
genes, including antioxidant enzymes, drug transporters
and drug-metabolizing enzymes [13,15]. The importance
of Keap1 is underlined in Keap1-deficient mice, which die
postnatally and have a constitutive Nrf2 activation [17].
In vitro suppression of Keap1 in human prostate and non-
small cell lung carcinoma cell lines results in an increased
Nrf2 activity and further to sensitization to various che-
motherapeutic agents and radiotherapy [18,19].
We recently demonstrated that nuclear Nrf2 expression
associates with poor survival in pancreatic adenocarcinomas
[20]. Partly as a continuation to that study, our specific aim
was here to evaluate the role of both Keap1 and 8-OHdG in
an independent material of pancreatic adenocarcinomas.
Methods
Samples
The study material consisted of 69 formalin-fixed, histo-
logical paraffin-embedded pancreatic adenocarcinoma
samples. The samples were fixed in neutral formalin,
embedded in paraffin blocks and stored at the
Department of Pathology, Oulu University Hospital.
Diagnoses were made during years 1993–2011 and 61
(88.4%) of them were diagnosed in 2000’s. All patients
were diagnosed and treated at Oulu University Hospital,
Finland. Only patients with at least palliative surgery
were included to enable sufficient histological samples
for reliable immunostaining evaluation. Mean follow-up
time was 24.3 months (range 1–172 months). Patient
characteristics are more precisely described in Table 1.
The study was approved by the Ethics Committee of the
Northern Ostrobothnia Hospital District and Finnish
National Supervisory Authority for Welfare and Health.Immunohistochemistry
The paraffin-embedded pancreatic lesions were first sec-
tioned on slides of 3 μm thickness and placed on Super-
FrostPlus glass (Menzel–Glāser, Germany). The sections
were de-paraffinized in xylene and rehydrated in a graded
alcohol series and washed in 10 mM phosphate-buffered
saline (PBS). To predigest the sections, they were placed
in a microwave oven and boiled in 10 mM citric acid
monohydrate (pH 6.0) for 12 minutes (8-OHdG) or in
Tris-EDTA (pH 9.0) for 15 minutes (Keap1) and cooled
for 30 minutes at room temperature. The sections were
flooded in 1% hydrogen peroxide in methanol for 15 min
(8-OHdG) or in 3% hydrogen peroxide in methanol for
10 min (Keap1) to consume the endogenous peroxide.
The sections were incubated 1 hour at +37°C with mouse
monoclonal 8-OHdG antibody (Japan Institute for the
Control of Aging, Fukuroi, Japan) using 1:50 dilution.
After washing with PBS the slides were incubated with
biotinylated secondary antibody (Invitrogen Corporation,
California, USA) for 20 minutes at room temperature and
Figure 1 Strong nuclear positivity of 8-OHdG (A) and cytoplasmic
and membrane bound Keap1 expression (B) in pancreatic ductal
adenocarcinoma.
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perature in streptavidin-peroxidase (Invitrogen Corporation,
California, USA). With Keap1, the slides were incubated
with a 1:300 primary antibody dilution Keap1 E20 (Santa
Cruz Biotechnology, Inc.) overnight at +4°C. The specificity
of used antibody Keap1 E20 has been confirmed previ-
ously with western blotting [21,22]. Next morning the sec-
tions were incubated with Goat Probe (Biocare Medical,
LLC, California, USA) for 15 minutes and after that the
sections were incubated with Goat-on-Rodent HRP-Polymer
(Biocare Medical, LLC, California, USA) for another
15 minutes. Dako Envision peroxidase detection system
(Dako K5007) was used as a chromogen in both immu-
nostainings and the sections were then counterstained with
haematoxylin and finally mounted with Immu-Mount
(Shandon, Pittsburgh, PA, USA).
Negative controls were produced by using the same
procedure except that the primary antibodies (8-OHdG
and Keap1) were replaced with PBS.
Immunohistochemical stainings were evaluated by expe-
rienced histopathogist (KMH). Both 8-OHdG and Keap1
immunostainings were divided to four class according to
their intensity in malignant cells: − = no immunoreactivity
observed; + = weak immunostaining; ++ =moderate im-
munostaining; +++ = strong immunostaining.
Statistical analysis
IBM SPSS Statistics 21.0.0.0 for Windows was applied
for statistical analysis. The reported p-values are from 2-
sided chi-square tests, except for survival analysis. Sur-
vival was analyzed by using Kaplan-Meier curves with
log-rank test and only pancreatic cancer-related death
was used as an endpoint. Cox regression analysis was
used in multivariate analysis. Relapse-free survival was
calculated from the operation date to the confirmed date
of relapse. T-class was divided in statistical analyses to
either T1-T2 or T3-T4 and grade was divided into either
grade I or grade II-III. Probability values below 0.05
were considered significant.
Results
In malignant cells Keap1 immunostaining was found in
cytoplasm and also on cell membranes. At places ex-
pression in membranes was even more prominent than
in cytoplasm. Nuclear Keap1 immunoreactivity was not
observed. 20 samples (29.0%) were totally negative for
cytoplasmic Keap1, 11 (15.9%) were graded as 1+, 21
(30.4%) as 2+ and 12 (17.4%) as 3+. On cell membranes
Keap1 was negative in 34 (49.3%) cases and 2+ in 30
(43.5%) cases, respectively. Keap1 expression was re-
corded in most cases in benign exocrine pancreas and in
the islets of Langerhans. It was also located to smooth
muscle tissue and to endothelium. Both cytoplasmic and
membrane-associated reactivity were present also in benigntissues. In addition, neutrophils had notable cytoplasmic
Keap1 expression. 8-OHdG expression was observed both
in nuclei and cytoplasm of cancer cells, although nuclear
staining was clearly more prevalent (Figure 1). 43 (62.3%)
samples did not show any 8-OHdG expression in nuclei,
22 (31.9%) were graded as 2+ and 4 samples (5.8%) as 3+.
In cytoplasm 8-OHdG was absent in 53 cases (76.8%),
staining corresponding 1+ was recorded in one patient
(1.4%), 2+ in 11 patients (15.9%) and 3+ in one patient
(1.4%). Five Keap1 and three 8-OHdG immunostainings
were missing due to exhaustion of blocks or because of
other technical challenges.
Cytoplasmic Keap1 expression associated with the ab-
sence of lymph mode metastases (p = 0.0009) and distant
metastases (p = 0.018) and non-significantly with high dif-
ferentiation (grade I) (p = 0.075). Nuclear 8-OHdG immu-
nostaining was overexpressed in patients with T1-T2
tumors (p = 0.016) and almost significantly in those with-
out lymph node involvement (p = 0.051). Strong cytoplas-
mic 8-OHdG expression associated with grade I tumors
(p = 0.023). Nuclear 8-OHdG and cytoplasmic Keap1 ex-
pressions associated with each other (p = 0.031).
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relapse-free survival (p = 0.041) and also with longer pan-
creatic cancer-specific survival (PCSS) (median survival 14
vs. 32 months; p = 0.029) (Figure 2). In Cox regression
analysis negative membranous Keap1 expression was an
independent prognostic factor of pancreatic cancer-
related death (hazard ratio 2.66, 95% confidence interval
1.23-5.75) when grade, tumor size and lymph node in-
volvement were taken into the model.
Discussion
The present results show that expression of Nrf2’s main
regulator, Keap1, is highly significant prognostic factor
in pancreatic adenocarcinomas in terms of RFS and
PCSS. These data give biological support to our recent
study, which demonstrated the association of Nrf2 ex-
pression and poor survival [20].
Continuous activation of proto-oncogene Nrf2 and over-
expression of Nrf2-targeted genes such as heme oxygenase-1Figure 2 Kaplan-Meier curves showing pancreatic cancer-specific
survival (A) and relapse-free survival (B) according to Keap1
expression in membranes.(HO-1), glutathione S-transferases and thioredoxin re-
ductase 1 are observed in several solid carcinomas [23].
The alterations in the repressor of Nrf2, Keap1 may ac-
tivate Nrf2-regulated antioxidant response pathway at
least 1) by achievement of somatic Keap1 mutations to
disturb Nrf2/Keap1 interaction 2) by epigenetic silencing
via methylation of Keap1 resulting in nuclear accumula-
tion of Nrf2 3) by cysteine residual modifications of Keap1
[15,18,23,24]. There are no recognized germ-line muta-
tions of Keap1, but somatic mutations have been reported
in various carcinomas [25]. In pancreatic carcinomas only
synonymous mutations of Keap1 have been reported [26]
but interestingly in the context of pancreatic cancer biol-
ogy, Keap1 mutations in other cancers seem to be more
considerably prevalent in adenocarcinomas and in patients
with smoking history [25].
According to our knowledge, there is only one previ-
ous study evaluating Keap1 expression in pancreatic
cancer in humans [26]. The authors reported no associa-
tions between Keap1 and clinicopathological parameters,
however, material was smaller than ours and no survival
analysis was performed. In the present study cytoplasmic
Keap1 expression was tightly connected to reduced meta-
static tendency, both to lymph nodes and to distant sites.
Cytoplasmic Keap1 likely reflects Nrf2-bound complexes,
which results in Nrf2’s ubiquitination and inhibition of its
function and subsequently ARE and Nrf2 target genes are
inactivated. These genes include HO-1, which play a cen-
tral role in pancreatic cancer metastasis formation by in-
ducing angiogenesis in co-operation with PTEN, which
predicts worse survival in several studies [25,27]. The
function of membrane-associated Keap1 is not as obvious,
but previous immunolocalization study found Keap1 also
as a component of cell-cell junctions and also in focal ad-
hesions and the authors suggested that Keap1 may also
have actin-binding properties [28].
Despite of protection against metastatic potential,
cytoplasmic Keap1 expression did not have impact to sur-
vival curves. Instead, Keap1 expression associated in cell
membranes had a significant protective effect on survival
in multivariate analysis, with median pancreatic cancer-
specific survival more than doubled. The magnitude of
Keap1’s protective value may therefore be even more
prominent than previously reported Nrf2 expression [20].
There were no long-time survivors in patients with nega-
tive membranous Keap1 immunostaining, whereas in
those with Keap1 expression there was a plateau in sur-
vival curve during five follow-up years. Even more strik-
ingly, in the group having membranous Keap1 expression,
46.3% of patients did not develop a relapse, which can be
considered as a substantial proportion among these pa-
tients. Rare previous data from other carcinomas shows
that in squamous non-small cell lung carcinoma Keap1
expression likewise associated with better survival with
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ously shown that there is aberrant Keap1 methylation in
triple-negative breast cancer (TNBC) and Keap1 overex-
pression is associated with poor prognosis in TNBC
[30,31]. In breast cancer paradoxical connection between
Keap1 and worse survival may derive from the sensitive
induction of Keap1 in stressed tumors, rather than car-
cinogenesis promoting features of Keap1 itself as dis-
cussed previously [31].
Association between nuclear 8-OHdG and cytoplasmic
Keap1 expressions probably derives from decreased nu-
clear DNA damage after Keap1 downregulation and
resulting activation of Nrf2’s target genes in ARE. Former
studies using Comet assay or HPLC-EC have suggested
higher levels of oxidative DNA damage in pancreatic tu-
mors than in benign pancreatic tissue [32], but studies
correlating 8-OHdG and clinicopathological parameters
or survival are lacking. We found no association between
8-OHdG expression and either RFS or PCSS, but the pres-
ence of nuclear 8-OHdG was connected to smaller primary
tumor size and the absence of lymph node metastases.
Cytoplasmic 8-OHdG also correlated with better differenti-
ation. In nuclei 8-OHdG is considered as damage marker
after •OH attacks to guanosine and based on our recent
data from transmission electron microscope studies on
Hodgkin lymphomas, cytoplasmic 8-OHdG expression is
likely to reflect mitochondrial DNA adducts and damage in
mRNA, tRNA, or rRNA [33]. 8-OHdG is one of the most
applied markers of oxidative stress and its immunohisto-
chemical expression has been connected to poor survival in
melanoma, colorectal cancer, diffuse large B-cell lymphoma
and in ovarian carcinoma [34-39]. Nevertheless, excessive
oxidative stress may lead to growth restriction or ultimately
to apoptosis [11]. This has been suggested as a hypothesis
why 8-OHdG expression is considerably attenuated in inva-
sive breast carcinomas compared with non-invasive breast
lesions and why high 8-OHdG levels have been constantly
associated with better prognosis in breast carcinomas
[30,38,39]. Furthermore, 8-OHdG expression is dependent
from DNA repair enzymes, especially from the function of
human 8-oxoguanine glycosylase (hOGG1). Association be-
tween more aggressive pancreatic carcinoma characteristics
and lower 8-OHdG expression may therefore result from
the induction of DNA repair enzymes under oxidative
stress, although this hypothesis remains to be confirmed.
Conclusions
In conclusion, this study adds data to the growing know-
ledge that highlights the importance of Keap1/Nrf2
pathway in human carcinomas. Although we had at least
sufficient follow-up and carefully collected clinicopatho-
gical data, sample size should be more considerable in
future studies validating the current results. We also
recommend the possible association between Keap1/Nrf2-axis and chemoresistance to be assessed in pro-
spective studies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JI participated in the evaluation of immunostaining, collected patient data,
helped with the statistical analysis, and drafted the manuscript. KMH
contributed to the study design, evaluated immunostaining results,
coordinated immunohistochemical staining, and provided comments on
drafts of the manuscript. PK and YS contributed to the study design,
statistical analyses, data interpretation, and writing of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The study was supported by the Finnish Cancer Society and the Finnish
Anti-tuberculosis Association.
Author details
1Department of Pathology, Medical Research Center Oulu, Oulu University
Hospital and University of Oulu, P.O. Box 50, 90020 Oulu University Hospital,
Finland. 2Department of Pathology and Forensic Medicine, University of
Eastern Finland, Cancer Center of Eastern Finland, PO Box 1627, 70211
Kuopio, Finland. 3Department of Oncology and Radiotherapy, Medical
Research Center Oulu, Oulu University Hospital and University of Oulu, P.O.
Box 22, 90029 Oulu University Hospital, Finland.
Received: 27 August 2014 Accepted: 25 March 2015
References
1. Yadav D, Lowenfels A. The epidemiology of pancreatitis and pancreatic
cancer. Gastroenterology. 2013;144:1252–61.
2. Boyle P, Levin B. Pancreas Cancer. In: World Cancer Report 2008.
International Agency for Research on Cancer. 2008. http://www.iarc.fr/en/
publications/pdfs-online/wcr/2008/wcr_2008.pdf. Accessed 7 Apr 2015.
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant
chemotherapy with gemcitabine vs observation in patients undergoing
curative-intent resection of pancreatic cancer: a randomized controlled trial.
JAMA. 2007;297:267–77.
4. Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, et al. An
undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer
cell invasiveness through reactive oxygen species-dependent, nuclear factor
κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4. Biol
Chem. 2013;288:21197–207.
5. Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-
edged sword with therapeutic potential. Oxid Med Cell Longev. 2010;3:23–4.
6. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. Reactive
oxygen species produced by NAD(P)H oxidase inhibit apoptosis in
pancreatic cancer cells. J Biol Chem. 2004;279:34643–34654.8.
7. Masamune A, Shimosegawa T. Signal transduction in pancreatic stellate
cells. J Gastroenterol. 2009;44:249–60.
8. Shimojo Y, Akimoto M, Hisanaga T, Tanaka T, Tajima Y, Honma Y, et al.
Attenuation of reactive oxygen species by antioxidants suppresses
hypoxia-induced epithelial-mesenchymal transition and metastasis of
pancreatic cancer cells. Clin Exp Metastasis. 2013;30:143–54.
9. Du J, Nelson ES, Simons AL, Olney KE, Moser C, Schrock HE, et al. Regulation
of pancreatic cancer growth by superoxide. Mol Carcinog. 2013;52:555–67.
10. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in
DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56.
11. Karihtala P, Soini Y. Reactive oxygen species and antioxidant mechanisms in
human tissues and their relation to malignancies. APMIS. 2007;115:81–103.
12. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis.
Annu Rev Pharmacol Toxicol. 2004;44:239–67.
13. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2,
Keap1: a historical overview. Antioxid Redox Signal. 2010;13:1665–78.
14. Kansanen E, Kuosmanen S, Leinonen H, Levonen AL. The Keap1-Nrf2
pathway: mechanisms of activation and dysregulation in cancer. Redox Biol.
2013;1:45–9.
Isohookana et al. Diagnostic Pathology  (2015) 10:28 Page 6 of 615. Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2-Keap1 antioxidant
response by the ubiquitin proteasome system: an insight into cullin-ring
ubiquitin ligases. Antioxid Redox Signal. 2010;13:1699–712.
16. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S,
et al. Keap1-null mutation leads to postnatal lethality due to constitutive
Nrf2 activation. Nat Genet. 2003;35:238–45.
17. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M,
et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer
cells causes chemoresistance and radioresistance and promotes tumor
growth. Mol Cancer Ther. 2010;9:336–46.
18. Zhan L, Zhang H, Zhang Q, Woods CG, Chen Y, Xue P, et al. Regulatory role
of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human
non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012;53:758–68.
19. Soini Y, Eskelinen M, Juvonen P, Kärjä V, Haapasaari K-M, Saarela A, et al.
Nuclear Nrf2 expression is related to a poor survival in pancreatic
adenocarcinoma. Pathol Res Pract. 2014;210:35–9.
20. Li CQ, Kim M, Godoy L, Thiantanawat A, Trudel L, Wogan G. Nitric oxide
activation of Keap1/nrf2 signaling in human colon carcinoma cells. Med Sci.
2009;106:14547–51.
21. Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, et al. PALB2 interacts with
KEAP1 To promote NRF2 nuclear accumulation and function. Mol Cell Biol.
2012;32:1506–17.
22. Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, et al. Methylation of the
KEAP1 gene promoter region in human colorectal cancer. BMC Cancer.
2012;12:66.
23. Adam J, Hatipoglu E, O’Flaherty L, Ternette N, Sahqal N, Lockstone H, et al.
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd
pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.
Cancer Cell. 2011;20:524–37.
24. Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez MC, García-Manero G.
Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med.
2013;65:750–64.
25. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, et al.
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation
and therapy. Mol Cancer. 2011;13:10–37.
26. Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, et al.
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic
cancer. Angiogenesis. 2003;6:15–24.
27. Velichkova M, Guttman J, Warren C, Eng L, Kline K, Vogl A, et al. A
homologue of Drosophila kelch associates with myosin-VIIa in specialized
adhesion junctions. Cell Motil Cytoskeleton. 2002;51:147–64.
28. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, et al. Nrf2
and Keap1 abnormalities in non-small cell lung carcinoma and association
with clinicopathologic features. Clin Cancer Res. 2010;16:3743–53.
29. Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, et al.
Aberrant Keap1 methylation in breast cancer and association with
clinicopathological features. Epigenetics. 2013;8:105–12.
30. Karihtala P, Kauppila S, Soini Y, Jukkola-Vuorinen A. Oxidative stress and
counteracting mechanisms in hormone receptor positive, triple-negative
and basal-like breast carcinomas. BMC Cancer. 2011;11:262.
31. Li D, Firozi PF, Zhang W, Shen J, DiGiovanni J, Lau S, et al. DNA adducts,
genetic polymorphisms, and K-ras mutation in human pancreatic cancer.
Mutat Res. 2002;513:37–48.
32. Bur H, Haapasaari K-M, Turpeenniemi-Hujanen T, Kuittinen O, Auvinen P,
Marin K, et al. Oxidative stress markers and mitochondrial antioxidant
enzyme expression are increased in aggressive Hodgkin lymphomas.
Histopathology. 2014; In press.
33. Sheridan J, Wang LM, Tosetto M, Sheahan K, Hyland J, Fennelly D, et al.
Nuclear oxidative damage correlates with poor survival in colorectal cance.
Brit J Cancer. 2009;100:381–8.
34. Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U. DNA adduct
8-hydroxydeoxyguanosine, a novel putative marker of prognostic
significance in ovarian carcinoma. Intl J Gynecol Cancer. 2009;19:1047–51.
35. Murtas D, Piras F, Minerba L, Ugalde J, Floris C, Maxia C, et al. Nuclear
8-hydroxy-2’deoxyguanosine as survival biomarker in patients with
cutaneous melanoma. Oncol Rep. 2010;23:329–35.
36. Soini Y, Haapasaari K-M, Vaarala MH, Turpeenniemi-Hujanen T, Kärjä V,
Karihtala P. 8-hydroxydeguanosine and nitrotyrosine are prognostic factors
in urinary bladder carcinoma. Int J Clin Exp Pathol. 2011;4:267–75.
37. Pasanen AK, Kuitunen H, Haapasaari K-M, Karihtala P, Kyllönen H, Soini Y,
et al. Expression and prognostic evaluation of oxidative stress markers in animmunohistochemical study of B-cell derived lymphomas. Leuk Lymphoma.
2012;53:624–31.
38. Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P.
8-Hydroxydeoxyguanosine: a new potential independent prognostic
factor in breast cancer. Brit J Cancer. 2010;102:1018–23.
39. Karihtala P, Kauppila S, Puistola U, Jukkola-Vuorinen A. Divergent behavior
of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and
4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology.
2011;58:854–62.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
